CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition.
Ali M NasserLisa MelamedEthan A WetzelJenny Chia-Chen ChangHiroaki NagashimaYosuke KitagawaLogan MuzykaHiroaki WakimotoDaniel P CahillJulie J MillerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
IDH-mutant gliomas with deletion of CDKN2A/B are sensitized to CDK4/6 inhibitors. These results support investigation of the use of these agents in a clinical setting.